E-LIB Suche - Ergebnisse für: Raimondo, Paola

1

Time to market access in Italy: duration of the P&R process..:

Marcellusi, Andrea ; Raimondo, Paola ; Galeone, Carlotta.
Global and Regional Health Technology Assessment. 10 (2023) - p. 79-88 , 2023

Link: https://doi.org/10.33393..

2

Erratum in: Cost per responder for upadacitinib vs abatacep..:

Caporali, Roberto ; Ravasio, Roberto ; Raimondo, Paola.
Global & Regional Health Technology Assessment. 9 (2022) - p. 30 , 2022

Link: https://doi.org/10.33393..

3

The costs incurred by patients to get eligibility to PCSK9 ..:

Bertolani, Arianna ; Ravasio, Roberto ; Raimondo, Paola.
Global & Regional Health Technology Assessment. 9 (2022) - p. 73-81 , 2022

Link: https://doi.org/10.33393..

4

Treatment management of patients with systemic lupus erythe..:

Sebastiani, Gian Domenico ; Mosca, Marta ; Ravasio, Roberto...
Global & Regional Health Technology Assessment. 9 (2022) - p. 123-132 , 2022

Link: https://doi.org/10.33393..

5

Cost per responder for risankizumab vs secukinumab in patie..:

Gisondi, Paolo ; Loconsole, Francesco ; Raimondo, Paola.
Global & Regional Health Technology Assessment. 8 (2021) - p. 120-130 , 2021

Link: https://doi.org/10.33393..

6

A Budget Impact Analysis of the VENTANA PD-L1 SP142 Immunoh..:

Scatena, Cristian ; Ravasio, Roberto ; Raimondo, Paola.
Farmeconomia. Health economics and therapeutic pathways. 22 (2021) 1 - p. , 2021

Link: https://doi.org/10.7175/..

7

Economic impact of Enterosgel® in the hospital treatment of..:

Ravasio, Roberto ; Raimondo, Paola
AboutOpen. 8 (2021) 1 - p. 99-105 , 2021

Link: https://doi.org/10.33393..

8

Cost per responder for upadacitinib vs abatacept in patient..:

Caporali, Roberto ; Ravasio, Roberto ; Raimondo, Paola.
Global & Regional Health Technology Assessment. 8 (2021) - p. 69-79 , 2021

Link: https://doi.org/10.33393..

9

AIFA time-to-reimbursement: a comparison between the last t..:

Raimondo, Paola ; Casilli, Giorgio ; Isernia, Martina...
Global & Regional Health Technology Assessment. 7 (2020) 1 - p. 109-114 , 2020

Link: https://doi.org/10.33393..

10

A Budget Impact Analysis of the VENTANA PD-L1 SP142 Immunoh..:

Scatena, Cristian ; Ravasio, Roberto ; Raimondo, Paola.
http://journals.seedmedicalpublishers.com/index.php/FE/article/view/1502/1883. , 2021

Link: http://journals.seedmedi..

11

A Budget Impact Analysis of the VENTANA PD-L1 SP142 Immunoh..:

Scatena, Cristian ; Ravasio, Roberto ; Raimondo, Paola.
http://journals.seedmedicalpublishers.com/index.php/FE/article/view/1502/1883. , 2021

Link: http://journals.seedmedi..

12

Time to market access in Italy: duration of the P&R process..:

Andrea Marcellusi ; Paola Raimondo ; Carlotta Galeone.
https://journals.aboutscience.eu/index.php/grhta/article/view/2610. , 2023

Link: https://doi.org/10.33393..

13

The costs incurred by patients to get eligibility to PCSK9 ..:

Arianna Bertolani ; Roberto Ravasio ; Paola Raimondo.
https://journals.aboutscience.eu/index.php/grhta/article/view/2415. , 2022

Link: https://doi.org/10.33393..

14

Erratum in: Cost per responder for upadacitinib vs abatacep..:

Roberto Caporali ; Roberto Ravasio ; Paola Raimondo.
https://journals.aboutscience.eu/index.php/grhta/article/view/2383. , 2022

Link: https://doi.org/10.33393..

15

Treatment management of patients with systemic lupus erythe..:

Gian Domenico Sebastiani ; Marta Mosca ; Roberto Ravasio...
https://journals.aboutscience.eu/index.php/grhta/article/view/2470. , 2022

Link: https://doi.org/10.33393..